Novartis Stock Forecast for 2022 - 2025 - 2030

Updated on 05/28/2022

Stock Rating
7 / 10
Price Target
CHF92.08
Consensus
Outperform
Upside
19.24%
Analysts
12
Stock Rating
0
Upside
19.24%
Analysts
12
Price Target
CHF92.08

The average price target for Novartis's stock of CHF92.08 recently provided by twelve leading analysts would represent a 19.24% upside from its last closing price if reached. This potential increase is based on a high estimate of CHF112.65 and a low estimate of CHF79.69. If you are not interested in NOVN stock, you may still be interested in its competitors and their current standings.

CHF92.08

19.24% Upside

Outperform
Outperform

Novartis Fair Value Forecast for 2022 - 2025 - 2030

In the last three years, Novartis's Fair Value has grown by 22.14%, rising from CHF81.99 to CHF100.14. For next year, analysts predict earnings per share of CHF106.55, which would mean an increase of 6.41%. Over the next nine years, experts predict that Novartis's Fair Value will grow at a rate of 76.05%.

2022 Fair Value Forecast
CHF106.55
2023 Fair Value Forecast
CHF114.64
2024 Fair Value Forecast
CHF122.74
2025 Fair Value Forecast
CHF130.79
2026 Fair Value Forecast
CHF139.43
2027 Fair Value Forecast
CHF148.25
2028 Fair Value Forecast
CHF157.29
2029 Fair Value Forecast
CHF166.67
2030 Fair Value Forecast
CHF176.29
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
LLY Stock Forecast Eli Lilly and Outperform 16
$323.48 $281.95 -0.77% 12
ABBV Stock Forecast AbbVie Outperform 9
$150.00 $164.23 11.83% 19
AZN Stock Forecast AstraZeneca PLC Outperform 18
£105.80 £136.08 37.87% 13
ABT Stock Forecast Abbott Laboratories Outperform 14
$116.69 $141.24 19.98% 19
BMY Stock Forecast Bristol-Myers Squibb Outperform 2
$76.14 $76.69 5.07% 16

Novartis Revenue Forecast for 2022 - 2025 - 2030

In the last three years, Novartis's Revenue has grown by 14.7%, rising from CHF46.10B to CHF52.88B. For next year, analysts predict earnings per share of CHF55.24B, which would mean an increase of 4.46%. Over the next nine years, experts predict that Novartis's Revenue will grow at a rate of 44.35%.

2022 Rev Forecast
CHF55.24B
2023 Rev Forecast
CHF57.51B
2024 Rev Forecast
CHF60.16B
2025 Rev Forecast
CHF62.70B
2026 Rev Forecast
CHF65.29B
2027 Rev Forecast
CHF67.99B
2028 Rev Forecast
CHF70.71B
2029 Rev Forecast
CHF73.49B
2030 Rev Forecast
CHF76.33B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
AMGN Stock Forecast Amgen Hold 7
$255.26 $246.46 -2.06% 13
CSL Stock Forecast CSL Outperform 0
$266.28 $228.01 -14.01% 10
MMM Stock Forecast 3M Hold 18
$149.51 $188.41 7.22% 17

Novartis Dividend per Share Forecast for 2022 - 2025 - 2030

In the last three years, Novartis's DPS has grown by 19.37%, rising from CHF2.84 to CHF3.39. For next year, analysts predict earnings per share of CHF3.59, which would mean an increase of 5.82%. Over the next nine years, experts predict that Novartis's DPS will grow at a rate of 48.48%.

2022 DPS Forecast
CHF3.59
2023 DPS Forecast
CHF3.78
2024 DPS Forecast
CHF3.92
2025 DPS Forecast
CHF4.11
2026 DPS Forecast
CHF4.29
2027 DPS Forecast
CHF4.46
2028 DPS Forecast
CHF4.65
2029 DPS Forecast
CHF4.84
2030 DPS Forecast
CHF5.03
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BDX Stock Forecast Becton, Dickinson and Outperform 17
$256.46 $270.20 11.13% 3
BAYN Stock Forecast Bayer Outperform 16
66.58€ 67.79€ 14.15% 14
BAS Stock Forecast BASF Outperform 18
51.11€ 78.27€ 25.22% 16

Novartis Free Cash Flow Forecast for 2022 - 2025 - 2030

Novartis's Free Cash Flow has seen inconsiderable growth in the last three years, rising from CHF13.02B to CHF13.69B – a growth of 5.19%. In the next year, analysts believe that Free Cash Flow will reach a reasonable CHF15.09B – an increase of 10.2%. For the next nine years, experts predict that Novartis's Free Cash Flow will grow at a rate of 133.67%.

2022 FCF Forecast
CHF15.09B
2023 FCF Forecast
CHF16.78B
2024 FCF Forecast
CHF18.80B
2025 FCF Forecast
CHF20.68B
2026 FCF Forecast
CHF22.74B
2027 FCF Forecast
CHF24.93B
2028 FCF Forecast
CHF27.17B
2029 FCF Forecast
CHF29.53B
2030 FCF Forecast
CHF32.00B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥2.83k ¥0.00 41.37% 0
BAX Stock Forecast Baxter International Outperform 17
$76.16 $89.29 18.17% 3
ALC Stock Forecast Alcon Outperform 0
CHF79.00 CHF0.00 15.3% 14

Novartis Net Income Forecast for 2022 - 2025 - 2030

In the past three years, Novartis's Net Income has seen significant growth, rising from CHF12.61B to CHF24.02B – a growth of 90.48%. In the next year, analysts believe that Net Income will reach a reasonable CHF33.57B – an increase of 39.74%. For the next nine years, the forecast is for Net Income to grow by 946.42%.

2022 NI Forecast
CHF33.57B
2023 NI Forecast
CHF49.25B
2024 NI Forecast
CHF70.05B
2025 NI Forecast
CHF91.06B
2026 NI Forecast
CHF116.75B
2027 NI Forecast
CHF145.84B
2028 NI Forecast
CHF177.45B
2029 NI Forecast
CHF212.80B
2030 NI Forecast
CHF251.36B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
DD Stock Forecast DuPont de Nemours Outperform 17
$68.36 $91.20 28.73% 7
BIIB Stock Forecast Biogen Outperform 11
$206.20 $287.21 10.33% 24
4503 Stock Forecast Astellas Pharma Outperform 0
¥1.80k ¥0.00 33.33% 0

Novartis EBITDA Forecast for 2022 - 2025 - 2030

Novartis's EBITDA has seen impressive growth in the last three years, rising from CHF14.11B to CHF17.15B – a growth of 21.62%. In the next year, analysts believe that EBITDA will reach an unimpressive CHF18.38B – an increase of 7.14%. For the next nine years, the forecast is for EBITDA to grow by 60.56%.

2022 EBITDA Forecast
CHF18.38B
2023 EBITDA Forecast
CHF19.54B
2024 EBITDA Forecast
CHF20.45B
2025 EBITDA Forecast
CHF21.62B
2026 EBITDA Forecast
CHF22.76B
2027 EBITDA Forecast
CHF23.89B
2028 EBITDA Forecast
CHF25.09B
2029 EBITDA Forecast
CHF26.30B
2030 EBITDA Forecast
CHF27.54B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
CHD Stock Forecast Church & Dwight Hold 18
$90.33 $88.52 9.6% 9
FRE Stock Forecast Fresenius SE & Co. KGaA Outperform 18
32.51€ 50.04€ 23.04% 6
ALNY Stock Forecast Alnylam Pharmaceuticals Outperform 7
$127.77 $209.00 60.05% 10

Novartis EBIT Forecast for 2022 - 2025 - 2030

In the past three years, Novartis's EBIT has grown by 20%, rising from CHF10.04B to CHF12.04B. For the next year, analysts predict that EBIT will reach CHF12.83B – an increase of 6.55%. Over the next nine years, experts believe that NOVN's EBIT will grow at a rate of 49.07%.

2022 EBIT Forecast
CHF12.83B
2023 EBIT Forecast
CHF13.44B
2024 EBIT Forecast
CHF13.97B
2025 EBIT Forecast
CHF14.64B
2026 EBIT Forecast
CHF15.27B
2027 EBIT Forecast
CHF15.91B
2028 EBIT Forecast
CHF16.59B
2029 EBIT Forecast
CHF17.26B
2030 EBIT Forecast
CHF17.95B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
4523 Stock Forecast Eisai Hold 16
¥6.85k ¥0.00 -3.61% 0
CRDA Stock Forecast Croda International Plc Outperform 18
£68.82 £85.37 26.42% 13
AFX Stock Forecast Carl Zeiss Meditec Hold 18
125.00€ 165.40€ 35.6% 1

Novartis EPS Price Prediction Forecast for 2022 - 2025 - 2030

In the last three years, Novartis's EPS has grown by 22.14%, rising from CHF5.15 to CHF6.29. For next year, analysts predict earnings per share of CHF6.69, which would mean an increase of 6.41%. Over the next nine years, experts predict that Novartis's EPS will grow at a rate of 76.05%.

2022 EPS Forecast
CHF6.69
2023 EPS Forecast
CHF7.20
2024 EPS Forecast
CHF7.71
2025 EPS Forecast
CHF8.22
2026 EPS Forecast
CHF8.76
2027 EPS Forecast
CHF9.31
2028 EPS Forecast
CHF9.88
2029 EPS Forecast
CHF10.47
2030 EPS Forecast
CHF11.07
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
ELAN Stock Forecast Elanco Animal Health Outperform 0
$26.31 $0.00 40.63% 8
EXAS Stock Forecast Exact Sciences Buy 8
$53.83 $144.24 71.84% 5
500124 Stock Forecast Dr. Reddy's Laboratories Outperform 0
Rp4.32k Rp5.47k 14.56% 12

© Copyright 2022 | Stock Forecast | All Rights Reserved